Visualizing Neighborhood COVID-19 Levels, Trends, and Inequities in Wastewater: An Equity-Centered Approach and Comparison to CDC Methods.
Saved in:
| Title: | Visualizing Neighborhood COVID-19 Levels, Trends, and Inequities in Wastewater: An Equity-Centered Approach and Comparison to CDC Methods. |
|---|---|
| Authors: | Cowger TL; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Link NB; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Hart JD; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Sharp MT; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Nair S; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Balasubramanian R; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Moallef S; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Chen J; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Hanage WP; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Tabb LP; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Hall KT; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Ojikutu BO; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Krieger N; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support., Bassett MT; François-Xavier Bagnoud (FXB) Center for Health and Human Rights (Dr Cowger, Ms Balasubramanian, Mr Moallef, and Dr Bassett), Department of Biostatistics (Mr Link), Center for Communicable Disease Dynamics (Ms Balasubramanian and Dr Hanage), Department of Social and Behavioral Sciences (Mr Moallef and Drs Chen, Krieger, and Bassett), Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Boston Public Health Commission, Boston, Massachusetts (Dr Cowger, Mr Hart, Ms Sharp, and Drs Nair, Hall, and Ojikutu); Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania (Dr Tabb); Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Drs Hall and Ojikutu); and Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts (Dr Ojikutu).; We thank the BPHC Infectious Disease Bureau (IDB), Office of Public Health Preparedness and Response (OPHPR) and Informatics Team for their assistance with data collection and analysis of COVID-19 clinical indicators and programmatic support. We thank Dr Rachel C. Nethery (HSPH) for her feedback and support in developing the methodology described herein. We thank our partners at Boston Water and Sewer Commission (BWSC) for their assistance with selection of sampling sites and programmatic support and collaboration that makes the program possible. We also thank our partners at Biobot Analytics and Flow Assessment Services for their assistance with sample collection, laboratory processing, data management and analysis, and programmatic support. |
| Source: | Journal of public health management and practice : JPHMP [J Public Health Manag Pract] 2025 Mar-Apr 01; Vol. 31 (2), pp. 270-282. Date of Electronic Publication: 2024 Sep 10. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9505213 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1550-5022 (Electronic) Linking ISSN: 10784659 NLM ISO Abbreviation: J Public Health Manag Pract Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
